Product
Anti-CD19 Universal CAR-T Cells
1 clinical trial
2 indications
Indication
B-cell Acute Lymphoblastic LeukemiaIndication
B-cell Non-Hodgkin LymphomaClinical trial
A Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Anti-CD19 Universal CAR-T Cells in the Treatment of CD19+ Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia and Relapsed/Refractory B-cell Non-Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2024-08-31